Australia Dermatology Treatment Drugs Market Analysis

$3,500.00$7,500.00

  • Type: Therapeutics Area
  • Published : February 2022
  • Region: APAC
  • Country: Australia
  • Report ID : 5104

  • Format: PPT, PDF

Australia Dermatology Treatment Drugs Market Analysis: Segmented by Drug Class, Drug Type, Prescription Mode, Indication, Route of Administration, End-User, Distribution Channel – Growth, Market Size, Future Prospects & Competitive Analysis, 2020 – 2028

Clear
SKU: 5104 Categories: ,

Report Description of the Australia Dermatology Treatment Drugs Market Analysis

Research Scope and Assumption

  • The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
  • The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
  • We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
  • All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
  • Inflation has not been accounted for in order to estimate and forecast the market
  • Numbers may not add up due to rounding off

Reason to buy the report:

  • Facilitate decision-making based on strong current and forecast data for Australia Dermatology Treatment Drugs Market Analysis
  • Develop strategies based on the latest regulatory framework
  • Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
  • Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Australia Dermatology Treatment Drugs Market Analysis
  • Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
  • To strategically profile key players and comprehensively analyze their market shares and core competencies
  • We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

Australia Dermatology Treatment Drugs Market Analysis Executive Summary

Australia is one of the important and emerging markets for organic and natural personal care products. According to Australian research, more than 4% of the population are affected by acne vulgaris in long term. The growing inclination towards skin health and care among millennials can have an excellent impact on the market growth in the forthcoming years. The increasing R&D investments by major companies owing to heavy demand for therapeutically effectual and cost-effective drugs will encourage the healthy growth of the market in the foreseeable future.

Market Size and Key Findings

The Australia Dermatology Treatment Drugs Market Analysis size stood at around USD xx% billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Market Dynamics

Market Growth Drivers Analysis

Skincare’s growth is attributable to the unique position it occupies amongst a variety of trends. The growing desire for health-promoting and self-care products, increasing interest in the power of regimens and routines, the ability of social media to more rapidly empower and inform consumers, and, uniquely, the ability of new technology to simplify the unusually complex choices consumers have when they interact with skincare brands. From artificial intelligence to 3D printing, augmented reality and DNA analysis, the beauty industry is becoming increasingly technology-driven. Personalization is a crucial area of development for beauty brands, tapping into consumer desire for products that can be customized to suit individual needs.

Market Restraints

Product recall of products having these drugs is expected to restraint the usage of dermatology drugs and is expected to slow down the growth of the dermatology drugs market in the forecasted period.

Covid-19 Market Impact Analysis

As the phase III COVID-19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology Group make the following preliminary recommendations around COVID-19 vaccination in dermatology patients on immunomodulatory and/or biologic agents.

  • Vaccination against COVID-19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents.
  • There are currently insufficient data to recommend one COVID-19 vaccine or vaccine type (mRNA, recombinant, inactivated virus) over another.
  • No specific additional risk in patients on immunomodulatory or biologic therapies has so far been identified.
  • Data on vaccine efficacy in patients on immunomodulatory or biologic therapies are missing, so standard vaccination protocols are recommended until otherwise advised.

Competitive Landscape

Key Players

The major players covered in the report are Novartis AG, Pfizer Inc., Eli Lilly and Company., Johnson & Johnson Services, Inc., Almirall, S.A, Mylan N.V., Sun Pharmaceutical Industries Ltd., UCB S.A., Belgium, Glenmark Pharmaceuticals Limited, Tolmar Pharmaceuticals, Inc., GlaxoSmithKline plc., Galderma Laboratories, L.P., Teva Pharmaceutical Industries Ltd., LEO Pharma A/S, MELINTA THERAPEUTICS, INC. – THE ANTIBIOTICS COMPANY, Mayne Pharma Group Limited, BIOFRONTERA AG, AbbVie Inc. among others.

Products in Pipeline

  • This interim advice is for clinicians treating patients with severe inflammatory skin disorders managed on conventional and newer immunomodulators. This includes systemic corticosteroids, azathioprine, ciclosporin, methotrexate and mycophenolate mofetil/mycophenolic acid, as well as the newer biologics for eczema and psoriasis including anti-TNF (e.g. adalimumab, certolizumab, etanercept, infliximab), anti-IL4/13 (dupilumab), anti-IL12/23 (ustekinumab), anti-IL17/23 (guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab), and small molecules such as PDE inhibitors (apremilast) and JAK inhibitors (abrocitinib, baricitinib, tofacitinib, upatacitinib).

Notable Recent Deals

  • In February 2019, Mayne Pharma Group Limited announced that they have launched the drug LEXETTE (halobetasol propionate) foam 0.05% in the United States.
  • In January 2020, Eli Lilly and Company announced that they have acquired Dermira, which is a biopharmaceutical company engaged in the introduction of novel therapies to treat the chronic skin conditions in a much better way. After this acquisition, the company will expand the pipeline of Lilly’s immunology with the addition of lebrikizumab which is a new monoclonal antibody designed to treat atopic dermatitis. This acquisition also expands the company portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium).

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The COVID-19 pandemic has led to most dermatologists in Australia gaining first-hand experience in teledermatology. Moving forward, hybrid teledermatology seems to be the preferred delivery method, using practical telehealth guidelines created for the Australian context. The results presented here include responses from a significant number of dermatologists who had not used telehealth before. They indicate that teledermatology may be most suited for ongoing care of patients on biologic therapy and with certain inflammatory conditions. For skin checks, specific set ups may be required.

The Australasian College of Dermatologists (ACD) is the peak medical college accredited by the Australian Medical Council for the training and professional development of medical practitioners in the specialty of dermatology. ACD is the leading authority in Australia for dermatology, providing information, advocacy and advice to patients, communities, government and other health stakeholders on skin health and dermatological practice. Medical practitioners who have successfully completed the training program of the ACD are known as Fellows of the College (FACD). Fellows of the College are recognised by the Medical Board of Australia as specialists in dermatology. Dermatologists maintain their professional standards and develop new skills through participation in the College’s continuing professional development (CPD) program.

1. Report Description of the Australia Dermatology Treatment Drugs Market Analysis
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. Australia Dermatology Treatment Drugs Market Analysis Executive Summary
2.1 Australia Dermatology Treatment Drugs Market Analysis – Industry Snapshot & key buying criteria, 2020-2028
2.2 Market Size, Growth Prospects and Key findings
3. Market Dynamics of Australia Dermatology Treatment Drugs Market Analysis
3.1 Market Growth Drivers Analysis
3.1.1 High Demand for Skin Care
3.1.2 Technology Advancement
3.2 Market Restraints Analysis
3.2.1 Product recall of products having these drugs
3.3 Covid-19 Market Impact Analysis
4. Australia Dermatology Treatment Drugs Market Segmentation
4.1 By Drug Class:
4.1.1 Corticosteroids
4.1.2 Retinoids
4.1.3 Monoclonal Antibodies
4.1.4 Antibiotics Agent
4.1.5 Antiviral Agents
4.1.6 Antifungal Drugs
4.1.7 Antihistamines Agents
4.1.8 Immunosuppressive Drugs
4.1.9 Others
4.2 By Drug Type:
4.2.1 Branded
4.2.2 Generics
4.3 By Prescription Mode:
4.3.1 Prescription based drugs
4.3.2 Over-the-counter drugs
4.4 By Indication:
4.4.1 Infectious Skin Disease
4.4.2 Inflammatory/Autoimmune Disorders
4.4.3 Pigmentation Disorders
4.4.4 Skin Cancer
4.4.5 Others
4.5 By Route of Administration:
4.5.1 Topical
4.5.2 Oral
4.5.3 Parenteral Administration
4.6 By End-User:
4.6.1 Homecare
4.6.2 Hospitals
4.6.3 Dermatology Clinics
4.7 By Distribution Channel:
4.7.1 Retail Pharmacy
4.7.2 Hospitals Pharmacy
4.7.3 Online Pharmacy
4.7.4 Others
5. Australia Dermatology Treatment Drugs Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
6.2 Products in Pipeline
6.3 R&D Initiatives Dermatology Drug Market
6.4 Notable recent deals in Dermatology Drug Market
6.4.1 Joint Ventures
6.4.2 Partnerships
6.4.3 Mergers & Acquisitions
6.4.4 Strategic divestments
7. Key Company Profiles
7.1 Abbvie Inc. Company overview
Product & Services, Strategies & Financials
7.2 Johnson & Johnson Services, Inc. Company overview
Product & Services, Strategies & Financials
7.3 GlaxoSmithKline Plc. Company overview
Product & Services, Strategies & Financials
7.4 Eli Lilly and Company overview
Product &, Strategies & Financials
7.5 Pfizer Inc. Company overview
Product & Services, Strategies & Financials
7.6 Glenmark Pharmaceuticals Ltd Company overview
Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
9. Factors Driving Future Growth
9.1 New Trends and Development of Dermatology Drug market
9.2 Future Opportunities
10. Strategic Recommendations

Australia Dermatology Treatment Drugs Market Analysis Segmentation

By Drug Class:

On the basis of drug class, the market is segmented into corticosteroids, retinoids, monoclonal antibodies, antibiotics agents, antiviral agents, antifungal drugs, antihistamines agents, immunosuppressive drugs and others. In 2020, corticosteroids segment is expected to dominate the market due to the first line treatment for various skin diseases. High volume of corticosteroids sold in the Asia-Pacific region.

By Drug Type:

On the basis of drug type, the market is segmented into branded and generics. In 2020, branded segment is expected to dominate the market due to the account of high penetration as a prescription drug in dermatological therapeutics segment.

By Prescription Mode:

On the basis of prescription mode, the market is segmented into prescription based drugs and over-the-counter drugs. In 2020, prescription based drugs segment dominates the Asia-Pacific dermatology drugs market, because maximum branded drugs sold via prescription based drugs mode over others in Asia-Pacific.

By Indication:

On the basis of indication, the market is segmented into infectious skin disease, inflammatory/autoimmune disorders, pigmentation disorders, skin cancer and others. In 2020, infectious skin disease segment dominates the Asia-Pacific dermatology drugs market, due to large patient pool for skin related disease in Asia-Pacific region which creates high demand for dermatology drugs.

By Route of Administration:

On the basis of route of administration, the market is segmented into oral, topical and parenteral. In 2020, topical segment dominates the Asia-Pacific dermatology drugs market; due to majority of dermatology drugs are available in cream, gels, ointment and others.

By End-User:

On the basis of end user, the market is segmented into homecare, hospitals, dermatology clinics and others. Homecare segment dominate the Asia-Pacific dermatology drugs market due to high volume demand from this end use. Majority of acne and psoriasis drugs were sold in the market by this end use.

By Distribution Channel:

On the basis of distribution channel, the market is segmented into retail pharmacy, hospitals pharmacy, online pharmacy and others. In 2020, retail pharmacy segment dominates the Asia-Pacific dermatology drugs market, due to well established retail distribution channel and cost effectiveness of this distribution channel.

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.



    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements